Global Variations in Patterns of Care for Retroperitoneal Sarcoma
Hayden Snow(Peter MacCallum Cancer Centre), David Gyorki(The University of Melbourne), Jason K. Sicklick(University of California San Diego), Dimitri Tzanis(Université Paris Cité), Dario Callegaro(Fondazione IRCCS Istituto Nazionale dei Tumori), Martin K. Angele(Ludwig-Maximilians-Universität München), Carol J. Swallow(University Health Network), Marco Fiore(Fondazione IRCCS Istituto Nazionale dei Tumori), Jing Xie(The University of Melbourne), Samuel Ford(University Hospitals Birmingham NHS Foundation Trust), Kenneth Cardona(Emory University), Ferdinando Cananzi(Humanitas University), Eran Nizri(Tel Aviv University), Marko Novak(Peter MacCallum Cancer Centre), Valerie P. Grignol(Ohio State University Hospital), Chandrajit P. Raut(Dana-Farber Cancer Institute), Sylvie Bonvalot(Dana-Farber Cancer Institute), Carolyn Nessim(University of Ottawa), D. Strauß(Royal Marsden Hospital), Alessandro Gronchi(Fondazione IRCCS Istituto Nazionale dei Tumori), Fabio Tirotta(University Hospitals Birmingham NHS Foundation Trust), Markus Albertsmeier(LMU Klinikum), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Mark Fairweather(Brigham and Women's Hospital), Winan J. van Houdt(Dutch Cancer Society), Michelle Wilkinson(Royal Marsden Hospital), Elisabetta Pennacchioli(European Institute of Oncology), Jacek Skoczylas(The Maria Sklodowska-Curie National Research Institute of Oncology), Sergio Valeri(Università Campus Bio-Medico), Joel Shapiro(Mount Sinai Hospital)
Cited by 6
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k